Recent content by jondoeuk

Positive long-term safety of KX-826 1.0%. https://en.kintor.com.cn/news_details/27.html

Pelage's Phase 2 trial for females. https://www.clinicaltrials.gov/study/NCT07907783 They have named the trial ''Awakening.'' They plan to recruit 200 adult female participants with androgenetic alopecia. With an age range of 18 to 65 years, and Savin Scale hair loss stages I-3, I-4, II-1, or...

New Awaken trial page. https://awakentrial.com/ The first patient has been dosed. https://pelagepharma.com/press-releases/pp405-awaken-trial-first-patient-dosed/

More positive data. https://www.biospace.com/press-releases/veradermics-achieved-the-highest-vdphl01-reported-hair-count-in-the-phase-3-program-to-date-in-positive-12-month-study-302-data-in-male-pattern-hair-loss ''VDPHL01, a novel orally-administered extended-release minoxidil formulation...

I said it looks to be more effective, not that it is. Standard oral minoxidil dissolves and absorbs quickly, causing a sharp blood concentration spike within about an hour that largely clears within four hours. VDPHL01 slowly dissolves over hours to provide a steady, extended release. VDPHL01...

Not yet as additional clinical trials are needed. Hopefully, more will start in the next few months.

Also of interest, the Reuters article on this has the following statement about the potential price of VDPHL01: ''The company said Nutrafol, a Unilever-backed hair-growth supplement that costs about $90 a month or about $1,000 a year, is a good price benchmark for its drug.''...

Veradermics announced positive top-line results from Part A of its phase three clinical trial (Study ‘304’). It entailed over 500 males with mild-to-moderate pattern hair loss who took oral VDPHL01 (extended-release oral minoxidil)...

It is safer. It looks to be more effective as well.

Rubedo announced plans to initiate a Phase 2a trial of RLS-1496 for androgenetic alopecia in October 2026...

Amplifica raised $26 million in a Series B Preferred Stock financing round. Of particular note, one of the investors is Eli Lilly (US), which also invested in Absci (US) earlier this year...

Amplifica published five-month results of a 61-person trial of AMP-303, described as a novel polysaccharide. https://www.jidonline.org/article/S0022-202X(25)01992-X/fulltext The male subjects (all aged 18-45) with mild to moderate androgenetic alopecia (Norwood III-IV) were divided into two...

Amplifica's AMP-303 phase one trial results came out: ''A statistically significant percentage of study subjects showed a greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment, and a greater than 10% increase compared to placebo at 150...

More here https://www.wired.com/story/a-hair-loss-study-raises-new-questions-about-aging-cells/

Kintor plans to initiate a phase IIb/III clinical trial of pyrilutamide in combination with minoxidil for the treatment of male androgenetic alopecia in China this year.